

Hiroshi Fukui

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8058580/publications.pdf>

Version: 2024-02-01

87
papers

8,308
citations

185998

28
h-index

82410

72
g-index

88
all docs

88
docs citations

88
times ranked

14169
citing authors

#	ARTICLE	IF	CITATIONS
1	Intestinal Permeability Is a Mechanical Rheostat in the Pathogenesis of Liver Cirrhosis. International Journal of Molecular Sciences, 2021, 22, 6921.	1.8	16
2	Leaky Gut and Gut-Liver Axis in Liver Cirrhosis: Clinical Studies Update. Gut and Liver, 2021, 15, 666-676.	1.4	54
3	Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites. Experimental and Therapeutic Medicine, 2021, 21, 30.	0.8	0
4	Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites. Experimental and Therapeutic Medicine, 2020, 21, 1-1.	0.8	2
5	Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far?. Diseases (Basel, Switzerland), 2019, 7, 58.	1.0	84
6	Platelet hyperaggregability is associated with decreased ADAMTS13 activity and enhanced endotoxemia in patients with acute cholangitis. Hepatology Research, 2018, 48, E52-E60.	1.8	10
7	von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C. United European Gastroenterology Journal, 2018, 6, 1401-1409.	1.6	27
8	Management of refractory cirrhotic ascites: challenges and solutions. Hepatic Medicine: Evidence and Research, 2018, Volume 10, 55-71.	0.9	18
9	Predictive parameter of tolvaptan effectiveness in cirrhotic ascites. Hepatology Research, 2017, 47, 854-861.	1.8	30
10	Treatment for cirrhotic ascites. Hepatology Research, 2017, 47, 166-177.	1.8	24
11	Decreased activity of plasma ADAMTS13 are related to enhanced cytokinemia and endotoxemia in patients with acute liver failure. Biomedical Reports, 2017, 7, 277-285.	0.9	23
12	Gut Microbiome-based Therapeutics in Liver Cirrhosis: Basic Consideration for the Next Step. Journal of Clinical and Translational Hepatology, 2017, 5, 249-260.	0.7	41
13	Improve gut microbiome: a new horizon of cancer therapy. Hepatobiliary Surgery and Nutrition, 2017, 6, 424-428.	0.7	6
14	A new link between innate immunity and hepatic metabolism: attractive unknown place to visit. Hepatobiliary Surgery and Nutrition, 2017, 6, 264-267.	0.7	2
15	Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation?. Inflammatory Intestinal Diseases, 2016, 1, 135-145.	0.8	247
16	Changes of Intestinal Functions in Liver Cirrhosis. Inflammatory Intestinal Diseases, 2016, 1, 24-40.	0.8	4,709
17	Evidence-based clinical practice guidelines for liver cirrhosis 2015. Journal of Gastroenterology, 2016, 51, 629-650.	2.3	253
18	Severe toxicity of chemotherapy against advanced soft tissue sarcoma in Werner's syndrome: Ifosfamide-induced encephalopathy with central diabetes insipidus. Journal of Orthopaedic Science, 2016, 21, 403-406.	0.5	4

#	ARTICLE	IF	CITATIONS
19	Gut Microbiota and Host Reaction in Liver Diseases. <i>Microorganisms</i> , 2015, 3, 759-791.	1.6	47
20	Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model. <i>Molecular Medicine Reports</i> , 2015, 11, 1693-1700.	1.1	62
21	Do vasopressin V2 receptor antagonists benefit cirrhotics with refractory ascites?. <i>World Journal of Gastroenterology</i> , 2015, 21, 11584.	1.4	22
22	Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia. <i>World Journal of Hepatology</i> , 2015, 7, 425.	0.8	141
23	Differential Expression of Drug Uptake and Efflux Transporters in Japanese Patients with Hepatocellular Carcinoma. <i>Drug Metabolism and Disposition</i> , 2014, 42, 2033-2040.	1.7	38
24	The Effect of Inflammatory Cytokines in Alcoholic Liver Disease. <i>Mediators of Inflammation</i> , 2013, 2013, 1-10.	1.4	183
25	Difficulty in evaluating intestinal permeability in patients with liver cirrhosis: What is the precipitating factor?. <i>Hepatology Research</i> , 2013, 43, 179-181.	1.8	0
26	Quality of ambulatory care provided by physicians-in-training for common diseases before and after the Japanese government reformed post-graduate medical education. <i>Tenri Medical Bulletin</i> , 2012, 15, 25-33.	0.1	0
27	Secondary aortoduodenal fistula identified by ultrasonography. <i>Journal of Medical Ultrasonics (2001)</i> , 2011, 38, 161-165.	0.6	5
28	Risk factors for the development of gastric mucosal lesions in rheumatoid arthritis patients receiving long-term nonsteroidal anti-inflammatory drug therapy and the efficacy of famotidine obtained from the FORCE study. <i>Modern Rheumatology</i> , 2009, 19, 629-636.	0.9	9
29	Potential Role of Enhanced Cytokemia and Endotoxemia on the Decreased Activity of Plasma ADAMTS13 in Patients with Alcoholic Hepatitis.. <i>Blood</i> , 2008, 112, 2292-2292.	0.6	1
30	Decreased Activity of Plasma ADAMTS13 Parallels Enhanced Endotoxemia in Patients with Severe Acute Pancreatitis: Relationship to Multiorgan Failure. <i>Blood</i> , 2008, 112, 4541-4541.	0.6	0
31	Plasma ADAMTS13 Activity Markedly Decreases in Patients with Severe Acute Pancreatitis: Its Potential Role on the Development of Multiorgan Failure.. <i>Blood</i> , 2007, 110, 2160-2160.	0.6	0
32	Relation of Endotoxin, Endotoxin Binding Proteins and Macrophages to Severe Alcoholic Liver Injury and Multiple Organ Failure. <i>Alcoholism: Clinical and Experimental Research</i> , 2005, 29, 172S-179S.	1.4	71
33	Cerebral Hemorrhage in Turner Syndrome: A Case Report. <i>Clinical Pediatric Endocrinology</i> , 2005, 14, 35-37.	0.4	5
34	Effect of Prostaglandin E Receptor Subtype EP4 Selective Agonist on the Secretion of Tumor Necrosis Factor-alpha by Macrophages in Acute Ethanol-Loaded Rats. <i>Alcoholism: Clinical and Experimental Research</i> , 2004, 28, 123S-128S.	1.4	2
35	Effect of Alcohol on the Secretion of Tumor Necrosis Factor-alpha by Macrophages in the Presence of Rat Serum. <i>Alcoholism: Clinical and Experimental Research</i> , 2002, 26, 81s-85s.	1.4	3
36	Analysis of the KAL1 Gene in 19 Japanese Patients with Kallmann Syndrome.. <i>Endocrine Journal</i> , 2001, 48, 143-149.	0.7	23

#	ARTICLE	IF	CITATIONS
37	Microscopic polyangiitis complicated with massive intestinal bleeding. <i>Journal of Gastroenterology</i> , 2001, 36, 264-270.	2.3	18
38	Hepatic adenomas treated with percutaneous ethanol injection in a patient with glycogen storage disease type Ia. <i>Journal of Gastroenterology</i> , 2001, 36, 52-61.	2.3	17
39	CASE OF HEMORRHAGE FROM A DUODENAL DIVERTICULUM TREATED SUCCESSFULLY BY ENDOSCOPIC INJECTIONS OF EPINEPHRINE. <i>Digestive Endoscopy</i> , 2001, 13, 27-32.	1.3	17
40	Endotoxin clearance and its relation to hepatic and renal disturbances in rats with liver cirrhosis. <i>Liver</i> , 2001, 21, 64-70.	0.1	32
41	The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells. <i>International Journal of Cancer</i> , 2001, 94, 768-773.	2.3	145
42	The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model. <i>Hepatology</i> , 2001, 33, 841-847.	3.6	49
43	Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. <i>Hepatology</i> , 2001, 34, 745-750.	3.6	346
44	Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. <i>Hepatology</i> , 2001, 34, 745-750.	3.6	22
45	Microscopic Polyangiitis That Presented Liver Dysfunction Prior to Noted Renal Manifestations.. <i>Internal Medicine</i> , 2000, 39, 517-521.	0.3	9
46	Immunomodulation with FK506 around the time of intravenous re-administration of an adenoviral vector facilitates gene transfer into primed rat liver. , 2000, 85, 839-844.		20
47	Electrochemotherapy for colorectal cancer with commonly used chemotherapeutic agents in a mouse model. <i>Digestive Diseases and Sciences</i> , 2000, 45, 1568-1577.	1.1	20
48	Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. <i>Hepatology</i> , 2000, 32, 1248-1254.	3.6	233
49	Plasma Endotoxin and Serum Cytokine Levels in Patients With Alcoholic Hepatitis: Relation to Severity of Liver Disturbance. <i>Alcoholism: Clinical and Experimental Research</i> , 2000, 24, 48S.	1.4	157
50	Prognostic Factors in Severe Alcoholic Liver Injury. <i>Alcoholism: Clinical and Experimental Research</i> , 1999, 23, 33S-38S.	1.4	23
51	Effects of "body compression" on parameters related to ascites formation: therapeutic trial in cirrhotic patients. <i>Journal of Gastroenterology</i> , 1999, 34, 75-82.	2.3	6
52	Disappearance of serum HCV-RNA after short-term prednisolone therapy in a patient with chronic hepatitis C associated with autoimmune hepatitis-like serological manifestations. <i>Journal of Gastroenterology</i> , 1999, 34, 269-274.	2.3	9
53	KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells. <i>Hepatology</i> , 1999, 30, 1179-1186.	3.6	90
54	Hepatocellular carcinoma in an orthotopic mouse model metastasizes intrahepatically in cirrhotic but not in normal liver. , 1999, 80, 471-476.		30

#	ARTICLE	IF	CITATIONS
55	Cytosine deaminase/5-fluorocytosine gene therapy can induce efficient anti-tumor effects and protective immunity in immunocompetent mice but not in athymic nude mice. , 1999, 81, 592-597.		36
56	A Novel Mutation of the KAL1 Gene in Kallmann Syndrome.. Endocrine Journal, 1999, 46, 651-658.	0.7	14
57	Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells. Hepatology, 1998, 28, 1489-1496.	3.6	97
58	Comparison of carcinoembryonic antigen promoter regions isolated from human colorectal carcinoma and normal adjacent mucosa to induce strong tumor-selective gene expression. , 1998, 78, 242-247.		19
59	Acute hepatic failure due to hepatosplenic B-cell non-Hodgkin's lymphoma in a patient infected with hepatitis C virus. Journal of Gastroenterology, 1998, 33, 880-885.	2.3	10
60	Effects of glycyrrhizin on immune-mediated cytotoxicity. Journal of Gastroenterology and Hepatology (Australia), 1997, 12, 243-248.	1.4	56
61	Effect of Treatment with Paromomycin on Endotoxemia in Patients with Alcoholic Liver Disease-A Double-Blind, Placebo-Controlled Trial. Alcoholism: Clinical and Experimental Research, 1997, 21, 1367-1373.	1.4	23
62	Radical esophagogastrectomy for unshuntable extrahepatic portal hypertension with bleeding varices: Report of a case. Surgery Today, 1997, 27, 243-246.	0.7	3
63	Tissue-specific expression of HSV-tk gene can induce efficient antitumor effect and protective immunity to wild-type hepatocellular carcinoma. , 1997, 71, 470-475.		26
64	Role of Albumin and High-Density Lipoprotein as Endotoxin-Binding Proteins in Rats with Acute and Chronic Alcohol Loading. Alcoholism: Clinical and Experimental Research, 1996, 20, 73a-76a.	1.4	28
65	Protective Mechanism of High-Density Lipoprotein against Endotoxemia in Chronic Alcohol Ingestion. Alcoholism: Clinical and Experimental Research, 1996, 20, 356A-359A.	1.4	5
66	Interaction of Kupffer cells to splenic macrophages and hepatocytes in endotoxin clearance: Effect of alcohol. Journal of Gastroenterology and Hepatology (Australia), 1995, 10, S31-S34.	1.4	12
67	Bystander effect caused by suicide gene expression indicates the feasibility of gene therapy for hepatocellular carcinoma. Hepatology, 1995, 22, 1838-1846.	3.6	76
68	Interferon treatment of chronic hepatitis C in patients with hemophilia or von Willebrand's disease in Japan. Journal of Gastroenterology, 1995, 30, 367-371.	2.3	12
69	A case of early gastric malignant lymphoma diagnosed and completely resected by strip biopsy. Journal of Gastroenterology, 1995, 30, 248-253.	2.3	2
70	Immunological Adverse Effects of Interferon Treatment. BioDrugs, 1995, 4, 361-375.	0.7	10
71	Stepped care medical treatment for cirrhotic ascites: Analysis of factors influencing the response to treatment. Journal of Gastroenterology and Hepatology (Australia), 1995, 10, 30-35.	1.4	10
72	Endotoxin inactivating action of plasma in patients with liver cirrhosis. Liver, 1995, 15, 104-109.	0.1	21

#	ARTICLE	IF	CITATIONS
73	Successful Hemostatic Management of Dieulafoy's Ulcer in Two Patients with Hemophilia A with Inhibitor. Japanese Journal of Thrombosis and Hemostasis, 1995, 6, 15-21.	0.1	0
74	Cysteinyl leukotrienes in the urine of patients with liver diseases. Hepatology, 1994, 20, 804-812.	3.6	37
75	Segmental transarterial chemoembolization with lipiodol mixed with anticancer drugs for nonresectable hepatocellular carcinoma: follow-up CT and therapeutic results. Cancer Chemotherapy and Pharmacology, 1994, 33, S60-S68.	1.1	63
76	Plasma endotoxin concentration and endotoxin binding capacity of plasma acute phase proteins in cirrhotics with variceal bleeding: An analysis by new methods. Journal of Gastroenterology and Hepatology (Australia), 1994, 9, 582-586.	1.4	11
77	Variant Type of Congenital Stomatocytosis.. Internal Medicine, 1994, 33, 103-106.	0.3	0
78	Endotoxaemia in patients with liver cirrhosis and upper gastrointestinal bleeding: Detection by the chromogenic assay with plasma Tween 80 pretreatment. Journal of Gastroenterology and Hepatology (Australia), 1993, 8, 577-581.	1.4	17
79	Exacerbation of Ulcerative Colitis during Alpha-Interferon Therapy for Chronic Hepatitis C.. Internal Medicine, 1993, 32, 327-331.	0.3	43
80	48,XXYY Syndrome Associated with Acromegaloidism.. Internal Medicine, 1993, 32, 160-165.	0.3	8
81	Imported <i>Plasmodium malariae</i> Malaria. Internal Medicine, 1993, 32, 355-355.	0.3	0
82	A case of imported <i>Plasmodium malariae</i> malaria.. Tropical Medicine and Health, 1993, 21, 127-130.	0.1	0
83	Chronic Active Epstein-Barr Virus Infection in an Adult.. Internal Medicine, 1992, 31, 1190-1196.	0.3	13
84	Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology, 1992, 16, 358-364.	3.6	228
85	Promoting effect of citrulline in hepatocarcinogenesis: Possible mechanism in hypercitrullinemia. Hepatology, 1990, 11, 819-823.	3.6	19
86	Plasma levels of atrial natriuretic peptide in patients with liver cirrhosis and its relation to ascites and renal function. Gastroenterologia Japonica, 1989, 24, 149-155.	0.4	4
87	Factor VIII procoagulant activity (VIII: C), factor VIII related antigen (VIII R: AG), and von Willebrand factor (VIII R: wF) in newborn cord blood and in pregnant maternal blood. Blood & Vessel, 1979, 10, 346-349.	0.0	0